Stryker (SYK)
(Delayed Data from NYSE)
$356.15 USD
-2.36 (-0.66%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $356.17 +0.02 (0.01%) 7:44 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$356.15 USD
-2.36 (-0.66%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $356.17 +0.02 (0.01%) 7:44 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Zacks News
Stryker Rallies 19.8% Year to Date: What's Driving the Stock?
by Zacks Equity Research
SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
If You Invested $1000 in Stryker a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
The Zacks Analyst Blog Toyota Motor, IBM, Stryker and Fossil Group
by Zacks Equity Research
Toyota Motor, IBM, Stryker and Fossil Group are included in this Analyst Blog.
Top Stock Reports for Toyota Motor, IBM & Stryker
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corporation (TM), International Business Machines Corporation (IBM) and Stryker Corporation (SYK), as well a micro-cap stock Fossil Group, Inc. (FOSL).
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio
by Zacks Equity Research
Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
Stryker (SYK) to Acquire care.ai to Boost AI-Driven Healthcare
by Zacks Equity Research
Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.
Stryker's (SYK) Pangea System to Enhance Plating Solutions
by Zacks Equity Research
Stryker (SYK) announces the launch of its Pangea Plating System, which is likely to provide solutions for internal fixation and stabilization of bone fractures.
Stryker (SYK) Completes MOLLI's Acquisition to Boost Business
by Zacks Equity Research
Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Compared to Estimates, Stryker (SYK) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.
Are Medical Stocks Lagging Stryker (SYK) This Year?
by Zacks Equity Research
Here is how Stryker (SYK) and Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) have performed compared to their sector so far this year.
Stryker (SYK) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 0.72% and 0.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can These 3 Medical Device Stocks Hit Earnings This Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how ECL, SYK and FMS are placed ahead of their earnings releases.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Seeking Clues to Stryker (SYK) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Stryker (SYK) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval
by Zacks Equity Research
Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.
Catalent (CTLT) Expands Its Facility Capabilities in Germany
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
Stryker (SYK) Completes Artelon's Acquisition to Boost Business
by Zacks Equity Research
Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
by Zacks Equity Research
DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
Patterson Companies (PDCO) Aims to Streamline Patient Experience
by Zacks Equity Research
Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
by Zacks Equity Research
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are a concern.